Our Portfolio
Light Sciences Oncology, Inc. (LSO), based in Snoqualmie, Washington, USA, developed an innovative light-activated treatment for solid tumors. LSO completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC), a Phase 3 trial for metastatic colorectal cancer and in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate.
The management team of the company currently includes Lisa Koch-Hulle, VP Clinical Operations and Regulatory Affairs, and Robert Littauer, VP and Chief Financial Officer.
Visit Website